Cargando…

Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions

BACKGROUND: Sirolimus has provided the option for calcineurin inhibitor (CNI)-free immunosuppressive therapy in both solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT). However, long-term use of sirolimus has been reported to be associated with a high incidence of cutane...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakrbarti, Aditi, Jaiswal, Sarita Rani, Chakrabarti, Suparno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681198/
https://www.ncbi.nlm.nih.gov/pubmed/26677273
http://dx.doi.org/10.4103/0019-5154.169131
_version_ 1782405719685857280
author Chakrbarti, Aditi
Jaiswal, Sarita Rani
Chakrabarti, Suparno
author_facet Chakrbarti, Aditi
Jaiswal, Sarita Rani
Chakrabarti, Suparno
author_sort Chakrbarti, Aditi
collection PubMed
description BACKGROUND: Sirolimus has provided the option for calcineurin inhibitor (CNI)-free immunosuppressive therapy in both solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT). However, long-term use of sirolimus has been reported to be associated with a high incidence of cutaneous side effects in SOT, particularly acneiform lesions. MATERIALS AND METHODS: We studied the incidence of acneiform lesions and the risk factors in 41 HSCT recipients between ages 4 and 64 years, undergoing HSCT for malignant (n = 29) and non-malignant diseases (n = 12) from haploidentical family donors. RESULTS: Seven patients developed acneiform lesions at the median of 85 days (range, 45–105 days). Acneiform lesions occurred in 6/11 patients on sirolimus and in only 1/30 patients not receiving sirolimus (P = 0.001). This was more frequent in patients with non-malignant disorders (5/12 versus 2/29, P = 0.01) and those receiving graft from female donors (7/23 versus 0/18, P = 0.01). CONCLUSIONS: Despite being frequently reported in SOT, this is the first such report in HSCT. Our study suggests that prolonged use of sirolimus might be associated with high incidence of acneiform lesions in haploidentical HSCT recipients with non-malignant diseases, particularly in those receiving graft from a female donor. We discuss the possible reasons for these findings and the putative mechanism of acneiform lesions in these patients
format Online
Article
Text
id pubmed-4681198
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-46811982015-12-16 Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions Chakrbarti, Aditi Jaiswal, Sarita Rani Chakrabarti, Suparno Indian J Dermatol Short Communication BACKGROUND: Sirolimus has provided the option for calcineurin inhibitor (CNI)-free immunosuppressive therapy in both solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT). However, long-term use of sirolimus has been reported to be associated with a high incidence of cutaneous side effects in SOT, particularly acneiform lesions. MATERIALS AND METHODS: We studied the incidence of acneiform lesions and the risk factors in 41 HSCT recipients between ages 4 and 64 years, undergoing HSCT for malignant (n = 29) and non-malignant diseases (n = 12) from haploidentical family donors. RESULTS: Seven patients developed acneiform lesions at the median of 85 days (range, 45–105 days). Acneiform lesions occurred in 6/11 patients on sirolimus and in only 1/30 patients not receiving sirolimus (P = 0.001). This was more frequent in patients with non-malignant disorders (5/12 versus 2/29, P = 0.01) and those receiving graft from female donors (7/23 versus 0/18, P = 0.01). CONCLUSIONS: Despite being frequently reported in SOT, this is the first such report in HSCT. Our study suggests that prolonged use of sirolimus might be associated with high incidence of acneiform lesions in haploidentical HSCT recipients with non-malignant diseases, particularly in those receiving graft from a female donor. We discuss the possible reasons for these findings and the putative mechanism of acneiform lesions in these patients Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4681198/ /pubmed/26677273 http://dx.doi.org/10.4103/0019-5154.169131 Text en Copyright: © 2015 Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Chakrbarti, Aditi
Jaiswal, Sarita Rani
Chakrabarti, Suparno
Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title_full Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title_fullStr Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title_full_unstemmed Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title_short Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions
title_sort sirolimus as long-term graft-versus-host-disease prophylaxis in haploidentical hematopoietic stem cell transplant recipients for non-malignant disorders is associated with high incidence of acneiform lesions
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681198/
https://www.ncbi.nlm.nih.gov/pubmed/26677273
http://dx.doi.org/10.4103/0019-5154.169131
work_keys_str_mv AT chakrbartiaditi sirolimusaslongtermgraftversushostdiseaseprophylaxisinhaploidenticalhematopoieticstemcelltransplantrecipientsfornonmalignantdisordersisassociatedwithhighincidenceofacneiformlesions
AT jaiswalsaritarani sirolimusaslongtermgraftversushostdiseaseprophylaxisinhaploidenticalhematopoieticstemcelltransplantrecipientsfornonmalignantdisordersisassociatedwithhighincidenceofacneiformlesions
AT chakrabartisuparno sirolimusaslongtermgraftversushostdiseaseprophylaxisinhaploidenticalhematopoieticstemcelltransplantrecipientsfornonmalignantdisordersisassociatedwithhighincidenceofacneiformlesions